人民财讯10月26日电，10月22日，通用技术中国医药与泸州老窖（000568）股份有限公司一行开展座 谈。双方围绕深化现有业务及大健康产业合作机遇、品牌资源协同、电商业务模式创新等方面展开深入 交流并达成初步共识，为后续深化战略合作、拓展业务领域奠定基础。 ...

Core Insights - The CXO (Contract X Organization) model allows pharmaceutical companies to outsource drug development, production, or sales to specialized institutions, enhancing efficiency and reducing costs while sharing the benefits of pharmaceutical innovation [1][2][4] - The global CXO market is projected to reach $196.6 billion by 2025, with a CAGR of 14.0% from 2021 to 2025, while the Chinese market is expected to grow to 247.7 billion yuan, with a remarkable CAGR of 26.56% from 2020 to 2025 [1][7][9] - Recent policies in China, such as the MAH (Marketing Authorization Holder) system, are optimizing resource allocation and encouraging innovation, providing a robust support system for the CXO industry [5][10] CXO Industry Overview - CXO encompasses various outsourcing services including CRO (Contract Research Organization), CMO (Contract Manufacturing Organization), CDMO (Contract Development and Manufacturing Organization), and CSO (Contract Sales Organization) [2][4] - The CXO industry is characterized by a full-process collaboration model that integrates services from early research to commercial production, significantly improving client R&D efficiency [4][10] Policy Analysis - Recent Chinese policies have created a favorable environment for the CXO industry, promoting innovation and optimizing the pharmaceutical supply chain [5][10] - The implementation of the MAH system has separated drug marketing and production licenses, enhancing specialization and reducing redundant investments [5][10] Global Market Trends - The global CXO market is experiencing rapid expansion, driven by increased R&D investments from innovative pharmaceutical companies [6][9] - By 2025, the global CRO market is expected to reach approximately $98 billion, while the CDMO market is projected to reach $99 billion, indicating strong growth potential [6][9] Chinese Market Dynamics - China's CXO market is rapidly expanding, with a projected market size increase from 76.3 billion yuan in 2020 to 247.7 billion yuan by 2025, reflecting a strong domestic market vitality [7][9] - In the first eight months of 2025, domestic innovative drug financing reached $7.75 billion, a year-on-year increase of 89%, highlighting the growing investment interest in the sector [9][10] Competitive Landscape - The Chinese CXO industry features a clear competitive hierarchy, with leading companies like WuXi AppTec and Kanglong Chemical expanding their market share through comprehensive service capabilities [10] - The first-tier companies are establishing a global delivery system, while second-tier companies are focusing on niche areas to build competitive advantages [10] Future Development Trends - The CXO industry is expected to evolve around three main directions: technological advancement, global operations, and ecosystem integration [10][12] - Leading companies will focus on high-tech areas such as ADC and gene therapy, while also enhancing their global operational resilience [12][13] - The integration of AI in drug development will drive new service models and reshape the competitive landscape, with larger firms consolidating their positions while smaller firms must specialize to survive [14]

相关报告：智研咨询发布的《2025-2031年中国医药制造行业市场发展态势及前景战略研判报告》 根据中国海关数据显示：2025年4月中国医药材及药品进口数量为3.85万吨，同比增长0.2%，进口金额 为40.89亿美元，同比下降11.2%，2025年4月中国医药材及药品出口数量为15万吨，同比增长17.8%，出 口金额为22.21亿美元，同比增长7.6%。 近一年中国医药材及药品进口情况统计图 数据来源：中国海关，智研咨询整理 近一年中国医药材及药品出口情况统计图 数据来源：中国海关，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 ...

Group 1 - Pinggao Electric reported a 6.98% increase in revenue to 8.436 billion yuan and a 14.62% increase in net profit to 982 million yuan for the first three quarters of 2025 [1] - Wanchen Group achieved a 77.37% increase in revenue to 36.562 billion yuan and a staggering 917.04% increase in net profit to 855 million yuan for the first three quarters of 2025 [2] - Xintian's revenue decreased by 10.42% to 481 million yuan, with a net profit decline of 35.19% to 91.9 million yuan for the first three quarters of 2025 [3] Group 2 - Chuangye Heima reported a revenue drop of 35.68% to 102 million yuan and a net loss of 24.93 million yuan for the first three quarters of 2025 [4] - Huaxin New Materials saw a 16.11% increase in revenue to 265 million yuan and an 18.56% increase in net profit to 40.81 million yuan for the first three quarters of 2025 [5] - Meihua Medical's revenue increased by 3.28% to 1.194 billion yuan, but net profit fell by 19.25% to 208 million yuan for the first three quarters of 2025 [6] Group 3 - Silica Technology reported a 24.30% increase in revenue to 2.651 billion yuan and a 44.63% increase in net profit to 229 million yuan for the first three quarters of 2025 [7] - Anada experienced a revenue decline of 6.03% to 1.31 billion yuan and a net loss of 46.37 million yuan for the first three quarters of 2025 [8] - StarNet Ruijie achieved a 19.20% increase in revenue to 14.168 billion yuan and a 31.06% increase in net profit to 344 million yuan for the first three quarters of 2025 [9] Group 4 - New Link Electronics reported a revenue decrease of 0.37% to 550 million yuan but a significant net profit increase of 421.43% to 535 million yuan for the first three quarters of 2025 [10] - Tianyin Electromechanical's revenue fell by 22.75% to 581 million yuan, with a net profit decline of 56.10% to 24.27 million yuan for the first three quarters of 2025 [11] - Hengtong Co. reported a revenue decrease of 39.29% to 1.05 billion yuan, but a net profit increase of 78.33% to 176 million yuan for the first three quarters of 2025 [12] Group 5 - Xigao Institute achieved a 15.05% revenue increase to 651 million yuan and a 21.28% net profit increase to 198 million yuan for the first three quarters of 2025 [13] - Good Housewife reported a revenue decrease of 0.91% to 1.059 billion yuan and a net profit decline of 24.79% to 143 million yuan for the first three quarters of 2025 [14] - China Pharmaceutical's subsidiary received approval for Vitamin B6 injection, indicating a positive development in its product pipeline [20] Group 6 - Xi Zhong Technology received approval for the issuance of convertible bonds, indicating potential for future capital raising [22] - Chengda Bio signed a strategic cooperation agreement with the Chinese Academy of Microbiology, focusing on infectious disease prevention [25] - Fuyuan Pharmaceutical received a drug registration certificate for Dydrogesterone tablets, enhancing its product offerings [26] Group 7 - Zhehai Deman received 8.1202 million yuan in land acquisition compensation, indicating a successful resolution of land-related issues [27] - Zhongjin Irradiation announced the resignation of its deputy general manager, indicating potential changes in management [29] - Hendi Pharmaceutical received a drug registration certificate for Febuxostat tablets, expanding its product portfolio [30] Group 8 - David Medical's subsidiary received a medical device registration certificate for a surgical stapler, enhancing its product offerings [32] - Liaoning Energy announced plans for a share reduction by a major shareholder, indicating potential changes in ownership structure [34] - Fengyuan Co. signed a framework agreement for the supply of lithium iron phosphate, indicating growth in its supply chain [35] Group 9 - Shengda Resources announced the resumption of construction at a mining site, indicating recovery from previous operational disruptions [37] - Shiyuan Co. reported a revenue increase of 5.45% to 18.087 billion yuan, but a net profit decline of 6.81% to 867 million yuan for the first three quarters of 2025 [39] - Feilida reported a revenue decrease of 6.81% to 4.659 billion yuan, but a net profit increase of 49.1% to 33.19 million yuan for the first three quarters of 2025 [40] Group 10 - Changyuan Donggu reported a revenue increase of 29.75% to 1.648 billion yuan and a net profit increase of 76.71% to 274 million yuan for the first three quarters of 2025 [41] - Liyuanheng reported a net profit of 47.49 million yuan for the first three quarters of 2025, indicating stable performance [42] - Fangyuan Co. reported a net loss of 121 million yuan for the first three quarters of 2025, indicating challenges in its operations [43] Group 11 - China Mobile reported a revenue increase of 0.4% to 794.7 billion yuan and a net profit increase of 4% to 115.4 billion yuan for the first three quarters of 2025 [44] - Huangshanghuang reported a revenue decrease of 5.08% to 1.379 billion yuan but a net profit increase of 28.59% to 101 million yuan for the first three quarters of 2025 [46] - Youcai Resources announced plans to invest approximately 150 million yuan in a new materials production base project [47] Group 12 - Huawei Technology announced plans to invest up to 20 million euros in two German subsidiaries [49] - China Shipbuilding projected a net profit increase of 144.42% to 170.85% for the first three quarters of 2025, indicating strong performance [51] - Aeston's subsidiary plans to transfer a 48% stake in a company for 245 million yuan, indicating strategic divestment [52] Group 13 - Jinxinno plans to raise up to 292 million yuan through a private placement, indicating potential for expansion [53] - China Power Construction reported a 5.04% increase in new contract amounts to 904.527 billion yuan for the first three quarters of 2025 [54] - Helitai reported a net profit increase of 101.45% to 17.81 million yuan for the first three quarters of 2025 [55] Group 14 - Xuefeng Technology reported a revenue decrease of 8.28% to 4.183 billion yuan and a net profit decline of 34.6% to 394 million yuan for the first three quarters of 2025 [57] - Juzhi Technology reported a revenue increase of 21.40% to 615 million yuan and a net profit increase of 33.78% to 82.47 million yuan for the first three quarters of 2025 [59] - Jinxi Axle reported a revenue decrease of 0.11% to 872 million yuan but a net profit increase of 268.03% to 22.11 million yuan for the first three quarters of 2025 [60] Group 15 - Longsheng Technology reported a revenue increase of 10.13% to 1.810 billion yuan and a net profit increase of 36.89% to 210 million yuan for the first three quarters of 2025 [62] - Shannon Chip Creation announced plans for a share reduction by a major shareholder, indicating potential changes in ownership structure [63]

10月15日，国家药品监督管理局发布第102号公告，决定注销氯雷他定片等80个药品注册证书。 根据《中华人民共和国药品管理法》相关规定，对疗效不确切、不良反应大或者因其他原因危害人体健康的药品，应当注销药品注 册证书。而这仅仅是冰山一角——据不完全统计，近一年内国家药监局已注销626个药品注册证书，其中89%为企业主动撤销。 在集采常态化、监管趋严、行业整合加速的多重压力下，中国医药行业正进入"大浪淘沙"的关键时期。曾经依靠"批文经济"躺赚的 时代已经终结，低质量仿制药的生存空间被急剧压缩。 这场淘汰赛不仅关乎企业的生死存亡，更将重塑整个行业的竞争格局。从扬子江药业占据氯雷他定市场近60%份额的"赢家通吃"， 到196家医药企业2024年宣布裁员的行业寒冬，一个更加集中、更加规范、更加残酷的新医药时代正在到来。 氯雷他定片的启示：百家争鸣背后的产能过剩困局 此次被注销的药品中，费森尤斯卡比华瑞制药有限公司(费卡华瑞)的氯雷他定片作为"领衔"品种，格外引人关注。这个看似不起眼 的抗过敏药物，恰恰是中国仿制药产能过剩问题的典型缩影。 氯雷他定作为第二代抗组胺药物，用于缓解过敏性鼻炎、荨麻疹等症状，市场需求相对稳定 ...

Market Overview - The pharmaceutical commercial sector increased by 0.55% on October 21, with First Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Stock Performance - First Pharmaceutical (600833) closed at 13.64, up 2.48% with a trading volume of 58,500 shares and a transaction value of 79.03 million yuan [1] - Other notable performers included: - Haiwang Biological (000078) at 2.55, up 2.41% [1] - HeFu China (603122) at 6.55, up 2.34% [1] - Ruikang Pharmaceutical (002589) at 2.93, up 2.09% [1] - Daclin (603233) at 18.67, up 1.52% with a transaction value of 293 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 105 million yuan from institutional investors and 110 million yuan from speculative funds, while retail investors saw a net inflow of 215 million yuan [2] - The capital flow for individual stocks showed mixed results, with China Pharmaceutical (600056) seeing a net inflow of 28.32 million yuan from institutional investors [3] Individual Stock Capital Flow - Key stocks with significant capital flow include: - China Pharmaceutical (600056) with a net inflow of 28.32 million yuan from institutional investors [3] - Jiuzhoutong (600998) with a net inflow of 24.77 million yuan from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 11.37 million yuan from institutional investors [3]

维生素 B6注射液主要用于维生素 B6缺乏的预防和治疗，防治异烟肼中毒，也可用于妊娠、放射病及抗 癌药所致的呕吐、脂溢性皮炎等，最早于1957年 6 月由日本扶桑药品工业株式会社研制，1972 年 8 月 获得FDA 批准在美国上市，规格 1ml:0.1g。目前原研产品未在国内进口上市。 格隆汇10月21日丨中国医药(600056.SH)公布，公司下属全资子公司天方药业收到国家药监局核准签发 的维生素B6注射液《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。 根据国家相关政策，通过一致性评价的药品品种在医保支付及医疗机构采购等领域将获得更大的支持力 度。天方药业的维生素 B6注射液通过仿制药质量和疗效一致性评价，有助于提升该药品的市场竞争 力，进一步拓展该药品的市场份额。 ...

证券代码：600056 证券简称：中国医药 公告编号：临 2025-080 号 中国医药健康产业股份有限公司 关于子公司获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的维生素B6注射液（以下简称"该药品"）《药 品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。现将有关 情况公告如下： 一、通知书基本信息 药品名称：维生素 B6注射液 受理号：CYHB2450491 通知书编号：2025B04781 剂型：注射剂 规格：1ml:0.1g 注册分类：化学药品 上市许可持有人：天方药业有限公司 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医 疗器械审评审批制度的意见》（国发〔2015〕44号）、《关于仿制药质量和疗效 一致性评价工作有关事项的公告》（2017年第100号）和《国家药监局关于开展 化学 ...

原创 苏浩 卢志坤 中经记者 苏浩 卢志坤 北京报道 一笔近亿元的业绩补偿款，一场围绕子公司股权的合同纠纷，中国医药（600056.SH）在法庭上赢得了阶段性胜利。 近期，中国医药发布公告称，其与西藏天晟泰丰药业股份有限公司（以下简称"西藏天晟"）及徐攀峰的业绩补偿合同纠纷案获北京市第二中级人民法院一审判决支持。法院判决西藏天晟向中国医 10月15日，中国医药方面在接受《中国经营报》记者采访时表示，对于合同纠纷的相关内容，中国医药已在公告中尽数披露，若西藏天晟选择继续上诉，中国医药也将积极应诉并于公告中披露 这场法律纠纷始于2024年10月，因业绩补偿问题，中国医药当时作为原告向北京市第二中级人民法院提起诉讼，将西藏天晟及徐攀峰告上法庭。 根据当时中国医药与西藏天晟、徐攀峰签署的《股权转让协议》，西藏天晟对河南通用2016年3月至2019年2月期间的净利润作出明确承诺。具体目标为：2016年3—12月不低于6841.67万元 2020年6月，经双方共同委托，大信会计师事务所对上述期间业绩完成情况进行了专项审计。审计结果显示，河南通用仅在2017年度超额完成256.01万元，其余时段均未达标：2016年3—12 ...

（中国医药涉合同纠纷公告公司公告/图） 一笔近亿元的业绩补偿款，一场围绕子公司股权的合同纠纷，中国医药（600056.SH）在法庭上赢得了 阶段性胜利。 近期，中国医药发布公告称，其与西藏天晟泰丰药业股份有限公司（以下简称"西藏天晟"）及徐攀峰的 业绩补偿合同纠纷案获北京市第二中级人民法院一审判决支持。法院判决西藏天晟向中国医药支付业绩 补偿款约9807.17万元及相应利息，徐攀峰对该债务承担连带清偿责任。 10月15日，中国医药方面在接受《中国经营报》记者采访时表示，对于合同纠纷的相关内容，中国医药 已在公告中尽数披露，若西藏天晟选择继续上诉，中国医药也将积极应诉并于公告中披露。 这场法律纠纷始于2024年10月，因业绩补偿问题，中国医药当时作为原告向北京市第二中级人民法院提 起诉讼，将西藏天晟及徐攀峰告上法庭。 根据当时中国医药与西藏天晟、徐攀峰签署的《股权转让协议》，西藏天晟对河南通用2016年3月至 2019年2月期间的净利润作出明确承诺。具体目标为：2016年3—12月不低于6841.67万元，2017年度不 低于9400万元，2018年度不低于1.1亿元，2019年1—2月不低于1840万元。 2 ...